Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at marketsectormovers.com, will continue to monitor these healthtech companies to see if the momentum continues. MarketSectorMovers.com is also looking into these tickers DAWN, COGT, RMD, BSX, RACE, RTX and more..
Recent ARWR Stock Price: $31.82
Summary: Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.
Mayank Mamtani analyst at B.Riley Financial reiterates coverage on Arrowhead Pharmaceuticals (ARWR) stock in the energy sector with a Buy rating and has set ARWR's stock price target at $ 59.
TipRanks.com reports that Arrowhead Pharmaceuticals currently has 8 analysts offering 12-month price targets on ARWR and the consensus is a Strong Buy rating with an average stock price target of $61.38. The most recent ARWR stock price we have is $31.82 and we are not making any ARWR forecasts at this time.
In addition, TradingView issued a Sell rating for ARWR over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ARWR. marketsectormovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ARWR, please click here >>
Prothena, PRTA
Recent PRTA Stock Price: $60.39
Summary: Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A'.'Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
Tazeen Ahmad analyst at Bank of America Securities reiterates coverage on Prothena (PRTA) stock in the energy sector with a Buy rating and has set PRTA's stock price target at $ 80.
TipRanks.com reports that Prothena currently has 8 analysts offering 12-month price targets on PRTA and the consensus is a Strong Buy rating with an average stock price target of $82.38. The most recent PRTA stock price we have is $60.39 and we are not making any PRTA forecasts at this time.
In addition, TradingView issued a Buy rating for PRTA over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on PRTA. marketsectormovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on PRTA, please click here >>
Amylyx Pharmaceuticals Inc, AMLX
Recent AMLX Stock Price: $38.52
Summary: Amylyx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It focuses on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc. is based in CAMBRIDGE, Mass.
Neena Bitritto-Garg analyst at Citigroup reiterates coverage on Amylyx Pharmaceuticals Inc (AMLX) stock in the energy sector with a Buy rating and has set AMLX's stock price target at $ 51.
TipRanks.com reports that Amylyx Pharmaceuticals Inc currently has 4 analysts offering 12-month price targets on AMLX and the consensus is a Strong Buy rating with an average stock price target of $47.75. The most recent AMLX stock price we have is $38.52 and we are not making any AMLX forecasts at this time.
In addition, TradingView issued a Buy rating for AMLX over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on AMLX. marketsectormovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on AMLX, please click here >>
Viridian Therapeutics, VRDN
Recent VRDN Stock Price: $26.84
Summary: Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.
Douglas Tsao analyst at H.C. Wainwright reiterates coverage on Viridian Therapeutics (VRDN) stock in the energy sector with a Buy rating and has set VRDN's stock price target at $ 35.
TipRanks.com reports that Viridian Therapeutics currently has 8 analysts offering 12-month price targets on VRDN and the consensus is a Strong Buy rating with an average stock price target of $40.88. The most recent VRDN stock price we have is $26.84 and we are not making any VRDN forecasts at this time.
In addition, TradingView issued a Buy rating for VRDN over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on VRDN. marketsectormovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on VRDN, please click here >>
The editors at marketsectormovers.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
MarketSectorMovers.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to MarketSectorMovers.com.
==============================================================================
